Recurrent miscarriage testing with Care Unity
CareUnity is a test which identifies one of the causes of recurrent miscarriage and other placental problems.
Recurrent Miscarriage Testing
After a miscarriage, its understandable that you want to know why it happened and what could be done to stop it happening again. However, unfortunately the miscarriage testing official guidelines only allows you to have tests or treatment after your third consecutive miscarriage. This is because most women who have one or two miscarriages will go on to have a successful pregnancy next time. At Care, our specific recurrent miscarriage test called Careunity can help provide you with much-needed answers and peace of mind.
What is CareUnity?
What Does Recurrent Miscarriage Testing Look For?
How does the Careunity recurrent miscarriage test work?
This screening test can identify the presence of the Annexin A5 gene. If the gene is present in either the sperm or the egg provider then there is at least a 50% chance it will be present in the embryo.
Initial saliva test
Testing for it is simple, a swab is taken from the inside of the mouth of both partners and the results are available in about 3 weeks.
Treatment for recurrent miscarriage
If the Annexin A5 Variant is identified in either partner the woman having embryo transfer will be prescribed a blood thinning medication called Heparin, better known as Clexane. This is an under the skin injection that starts at the time of embryo transfer and continues until at least 12 weeks of pregnancy.
The independent regulator of fertility treatment, the Human Fertilisation and Embryology Authority (HFEA) consider that the only way to be confident that a treatment is effective enough to be used routinely is to carry out a randomised controlled trial (RCT). In an RCT, patients are assigned randomly to two groups: a treatment group, given the new treatment and a control group, given either a well-tried treatment or a placebo.
The CAREunity test has not been subject to a Random Controlled Trial (RCT) and supporting evidence is limited. It is therefore important that you discuss with your consultant whether it is suitable for you before making a decision on whether to include the test in your treatment.